Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

IKZF1 Deletions Are Markers of Treatment Resistance in Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia Patients Treated within the Ongoing Risk-Adapted Pethema LAL19 Trial

Blood (2022) 140 (Supplement 1): 6345–6347.

https://doi.org/10.1182/blood-2022-162159

Published: 2022

Journal Articles

Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

Blood (2022) 140 (Supplement 1): 1109–1111.

https://doi.org/10.1182/blood-2022-168718

Published: 2022

Journal Articles

Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?

Blood (2022) 140 (Supplement 1): 9740–9743.

https://doi.org/10.1182/blood-2022-168599

Published: 2022

Journal Articles

Sequential Study By RNA-Seq Shows a Reduction in Inflammation and a Cell Cycle Activation in T-Lymphocytes from Myelodysplastic Syndrome with Del(5q) after Lenalidomide Treatment in Patients Included in the "Sintra-REV" Clinical Trial

Mónica Del Rey, Luis A Corchete, PhD, Teresa González, PhD, Félix López Cadenas, MD, Eva Lumbreras, Marta Martín Izquierdo, MSc, Sandra Santos-Mínguez, Sofía M Toribio, Blanca Xicoy, MD, Joaquín Sánchez-García, MD PhD, Teresa Bernal, MD PhD, Guillermo F Sanz, MD PhD, Benet Nomdedeu, MD, Pierre Fenaux, MD PhD, Jesús M Hernández Rivas, MD PhD, Maria Diez-Campelo, PhDMD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-140703

Published: 2020

Journal Articles

Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients - Interim Analysis of the European Sintra-REV Trial

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-140339

Published: 2020

Journal Articles

Integrated Transcriptomic and Proteomic Analyses of Inflammasome in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

María Zurdo, Ana M Hurtado López, Tzu Hua Chen-Liang, Helios Martínez-Banaclocha, Laura Palomo, Félix López Cadenas, MD, Eva Lumbreras, Blanca Xicoy, MD MSc, Lurdes Zamora, PhD, María Díez-Campelo, MD PhD, Francesc Sole, PhD, Pablo Pelegrín, Andres Jerez

Blood (2019) 134 (Supplement_1): 2991.

https://doi.org/10.1182/blood-2019-128094

Published: 2019

Journal Articles

Genomic Instability and a Preferential Involvement of Ras Pathway in the Myelodysplastic Syndromes Evolution to Secondary Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 3082.

https://doi.org/10.1182/blood-2018-99-118224

Published: 2018

Journal Articles

Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients with Del(5q) — Preliminary Blinded Analysis of the European Sintra-REV Trial

Blood (2018) 132 (Supplement 1): 468.

https://doi.org/10.1182/blood-2018-99-119430

Published: 2018

Journal Articles

Heterogeneous Landscape of RUNX1 Related Disorder: Four Families with Inherited Thrombocytopenias and Novel Genetic Variants in RUNX1 Associated to Relevant Clinical Complications

Jose Maria Bastida, MDPhD, Rocio Benito, Jesus M Hernández-Sánchez, Maria L Lozano, Kamila Janusz, Eva Lumbreras, Alvaro Lassaletta, Susana Riesco, Jorge Huerta, Veronica Palma-Barqueros, Ana Hortal, Maria Díez-Campelo, Maria Isabel Prieto-Conde, Maria Carmen Chillon, Consuelo Del Cañizo, MDPhD, Jesús M Hernández-Rivas, MD PhD, Jose Rivera, Jose Ramon González-Porras, MDPhD

Blood (2017) 130 (Supplement 1): 3647.

https://doi.org/10.1182/blood.V130.Suppl_1.3647.3647

Published: 2017

Journal Articles

Transcriptome of DNA Repair Genes in CMML: Rationale for Targeting ERCC1 and CDKN1A As a Synthetic Lethality Approach

Blood (2017) 130 (Supplement 1): 1679.

https://doi.org/10.1182/blood.V130.Suppl_1.1679.1679

Published: 2017

Journal Articles

Patterns of Clonal Evolution Assessed By Whole Exome Sequencing during Progression from MDS to AML Are Related to Therapy

María Abáigar, PhD, Jesús M Hernández-Sánchez, David Tamborero, PhD, Marta Martín-Izquierdo, María Díez-Campelo, MD, María Hernández-Sánchez, Fernando Ramos, MD, Marta Megido, Carlos Aguilar, Eva Lumbreras, Isabel Recio, Carmen Olivier, Cristina Robledo, Rocío Benito, PhD, Nuria Lopez-Bigas, Consuelo Del Cañizo, MD PhD, Jesús María Hernández-Rivas, MD

Blood (2016) 128 (22): 4309.

https://doi.org/10.1182/blood.V128.22.4309.4309

Published: 2016

Journal Articles

Could Chronic Gvhd Overcome the Poor Prognosis of Patients with MDS and TP53 Undergoing Allogeneic HSCT?

Juan Carlos Caballero, MD, Mercedes Sánchez-Barba, Mónica Del Rey, Kamila Janusz, Eva Lumbreras, María Abáigar, Robledo Cristina, Andrés Jerez, Esperanza Such, PhD, Guillermo Sanz, MD PhD, Cristina Calderon, MD, David Valcarcel, MD PhD, Jesus Maria Hernandez-Rivas, PhD, María Consuelo Cañizo, MD PhD, María Díez-Campelo, MD PhD

Blood (2015) 126 (23): 2890.

https://doi.org/10.1182/blood.V126.23.2890.2890

Published: 2015

Journal Articles

Downregulation of BAP1 in Chronic Myelomonocytic Leukemia: Correlated with a Post-Translational Reduction of BRCA1 Levels and Independent of Promoter Methylation

Ana María Hurtado, Gines Luengo-Gil, Laura Palomo, MSc, Eva Lumbreras, Eva Caparrós, Tzu Hua Chen-Liang, Bartlomiej Przychodzen, MSc, Maria Luz Amigo, María Díez-Campelo, MD PhD, Lurdes Zamora, PhD, Francisco José Ortuño, Raul Teruel Montoya, PhD, Jaroslaw P. Maciejewski, MD PhD, Consuelo Del Cañizo, MD PhD, Francesc Sole, PhD, Francisca Ferrer-Marin, Andres Jerez

Blood (2015) 126 (23): 1648.

https://doi.org/10.1182/blood.V126.23.1648.1648

Published: 2015

Journal Articles

Myelodysplastic Syndromes with I(17)(q10) and Prognostic Implications of Mutations of TP53 and SETBP1

Blood (2014) 124 (21): 1910.

https://doi.org/10.1182/blood.V124.21.1910.1910

Published: 2014

Journal Articles

Array CGH As a Complementary Tool in the Diagnosis of Myelodysplastic Syndromes

Blood (2012) 120 (21): 3827.

https://doi.org/10.1182/blood.V120.21.3827.3827

Published: 2012

Journal Articles

Prevalence of EVI1 Overexpression and Its Impact on Diagnosis and Prognosis in Acute Myeloid Leukemia: A Study of 490 Patients from the Spanish Group of Myeloid Malignancies of the RTICC.

Iria Vazquez, BSc, José Cervera, MD, PhD, Maria Gomez-Benito, Ph.D., Nerea Marcotegui, BSc, Miren Maicas, BSc, Ana Conchillo, Ph.D., Ana Valencia, Ph.D., Eva Lumbreras, Ph.D., Salut Brunet, MD, Maria T. Gómez-Casares, MD, Ph.D., Jesus-Maria Hernandez-Rivas, MD, Ph.D., Maria J. Calasanz, PhD, Jorge Sierra, MD, PhD, Maria D. Odero, MD, PhD

Blood (2008) 112 (11): 1515.

https://doi.org/10.1182/blood.V112.11.1515.1515

Published: 2008

Journal Articles

Imatinib Mesilate Modifies Genes Involved in Hematopoiesis in Non Clonal Bone Marrow Cells from CML Patients in Complete Cytogenetic Response.

Fermin M. Sanchez-Guijo, MD, PhD, Eva Lumbreras, BSc, Patricia Morais, BSc, Juan-Luis Garcia, PhD, Norma C. Gutierrez, MD, PhD, J.F. San Miguel, MD, PhD, Consuelo del Canizo, MD, PhD, Jesus M. Hernandez-Rivas, MD, PhD

Blood (2007) 110 (11): 2947.

https://doi.org/10.1182/blood.V110.11.2947.2947

Published: 2007

Journal Articles

Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma

Norma C. Gutiérrez, Juan L. García, Jesús M. Hernández, Eva Lumbreras, Mariana Castellanos, Ana Rasillo, Gema Mateo, José M. Hernández, Sonia Pérez, Alberto Orfao, Jesús F. San Miguel

Blood (2004) 104 (9): 2661–2666.

https://doi.org/10.1182/blood-2004-04-1319

Published: 2004

NARROW

IKZF1 Deletions Are Markers of Treatment Resistance in Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia Patients Treated within the Ongoing Risk-Adapted Pethema LAL19 Trial

Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?

Sequential Study By RNA-Seq Shows a Reduction in Inflammation and a Cell Cycle Activation in T-Lymphocytes from Myelodysplastic Syndrome with Del(5q) after Lenalidomide Treatment in Patients Included in the "Sintra-REV" Clinical Trial

Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients - Interim Analysis of the European Sintra-REV Trial

Integrated Transcriptomic and Proteomic Analyses of Inflammasome in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Genomic Instability and a Preferential Involvement of Ras Pathway in the Myelodysplastic Syndromes Evolution to Secondary Acute Myeloid Leukemia

Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients with Del(5q) — Preliminary Blinded Analysis of the European Sintra-REV Trial

Heterogeneous Landscape of RUNX1 Related Disorder: Four Families with Inherited Thrombocytopenias and Novel Genetic Variants in RUNX1 Associated to Relevant Clinical Complications

Transcriptome of DNA Repair Genes in CMML: Rationale for Targeting ERCC1 and CDKN1A As a Synthetic Lethality Approach

Patterns of Clonal Evolution Assessed By Whole Exome Sequencing during Progression from MDS to AML Are Related to Therapy

Could Chronic Gvhd Overcome the Poor Prognosis of Patients with MDS and TP53 Undergoing Allogeneic HSCT?

Downregulation of BAP1 in Chronic Myelomonocytic Leukemia: Correlated with a Post-Translational Reduction of BRCA1 Levels and Independent of Promoter Methylation

Myelodysplastic Syndromes with I(17)(q10) and Prognostic Implications of Mutations of TP53 and SETBP1

Array CGH As a Complementary Tool in the Diagnosis of Myelodysplastic Syndromes

Prevalence of EVI1 Overexpression and Its Impact on Diagnosis and Prognosis in Acute Myeloid Leukemia: A Study of 490 Patients from the Spanish Group of Myeloid Malignancies of the RTICC.

Imatinib Mesilate Modifies Genes Involved in Hematopoiesis in Non Clonal Bone Marrow Cells from CML Patients in Complete Cytogenetic Response.

Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only